成纤维细胞生长因子受体 2 基因融合对根治性切除术后肝内胆管癌患者生存的影响。
Impact of FGFR2 gene fusions on survival of patients with intrahepatic cholangiocarcinoma following curative intent resection.
机构信息
Department of Surgery, Mayo Clinic, Rochester, MN, USA.
Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA.
出版信息
HPB (Oxford). 2022 Oct;24(10):1748-1756. doi: 10.1016/j.hpb.2022.05.1341. Epub 2022 May 28.
BACKGROUND
Intrahepatic Cholangiocarcinoma (iCCA) is an aggressive cancer with diverse mutational profiles. An important molecular subtype is fibroblast growth factor receptor 2 (FGFR2) fusion. The effect of FGFR2 fusions on prognosis is unknown. Our aim was to assess the outcomes in resected CCA patients in relation to FGFR2 status.
METHODS
Surgically treated CCA patients from a single institution were retrospectively reviewed between 2008 and 2014. FGFR rearrangements were detected by fluorescence in situ hybridization (FISH). Data included patient demographics, tumor pathology, disease-free survival (DFS) and overall survival (OS).
RESULTS
Ninety-five patients underwent surgical resection for iCCA. Twelve (13%) of these were found to have FGFR2 fusion, none of which were treated with FGFR targeted therapy. Patients with FGFR2 fusions were found to have a longer 5-year (83 vs. 32%, p = 0.01) and 10-year (46 vs. 22%, p = 0.04) OS. Five and 10-year DFS was also increased (68 vs. 33% p = 0.04) and (68 vs. 25 %, p = 0.02,). FGFR2 fusion status was the strongest independent factor associated with improved OS (HR 0.23, 0.09-0.62, p=0.003) and DFS (HR 0.18, 0.05-0.67, p=0.01).
CONCLUSION
Patients with CCA FGFR2 fusion have improved OS and DFS following surgical resection.
背景
肝内胆管癌（iCCA）是一种具有多种突变特征的侵袭性癌症。一个重要的分子亚型是成纤维细胞生长因子受体 2（FGFR2）融合。FGFR2 融合对预后的影响尚不清楚。我们的目的是评估与 FGFR2 状态相关的接受手术治疗的 CCA 患者的结局。
方法
对 2008 年至 2014 年间在单一机构接受手术治疗的 CCA 患者进行回顾性研究。通过荧光原位杂交（FISH）检测 FGFR 重排。数据包括患者的人口统计学、肿瘤病理学、无病生存期（DFS）和总生存期（OS）。
结果
95 例患者接受手术切除 iCCA。其中 12 例（13%）发现 FGFR2 融合，均未接受 FGFR 靶向治疗。FGFR2 融合患者的 5 年（83%比 32%，p=0.01）和 10 年 OS（46%比 22%，p=0.04）均较长。5 年和 10 年 DFS 也有所提高（68%比 33%，p=0.04）和（68%比 25%，p=0.02）。FGFR2 融合状态是与改善 OS（HR 0.23，0.09-0.62，p=0.003）和 DFS（HR 0.18，0.05-0.67，p=0.01）最显著的独立相关因素。
结论
接受手术切除的 CCA FGFR2 融合患者的 OS 和 DFS 得到改善。
Zotero 插件